Journals / Bakırköy Tıp Dergisi / 2016 / Cilt: 12 - Sayı: 2

Is serum tenascin-C level potential biomarker in pancreatic adenocarcinoma?

Pankreas adenokarsinomunda serum tenascin-C düzeyi potansiyel bir biyobelirteç midir?

Pages
76–82
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Similarly, it was shown that serum TNC levels had no effect on overall survival (p=0.31).Conclusions: Serum TNC level is a diagnostic biomarker for patients with PA.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Tenascin-C (TNC) is an extracellular matrix protein involved in the tissue construction.
📊
Key Findings & Data:In this study, we aimed to determine the clinical significance of serum TNC levels in patients with pancreatic adenocarcinoma (PA).Materials and Methods: Thirty-three patients with histopathologically confirmed PA diagnosis and sex- and age-matched 30 healthy controls were included into the current study.
💡
Conclusion & Impact:Similarly, it was shown that serum TNC levels had no effect on overall survival (p=0.31).Conclusions: Serum TNC level is a diagnostic biomarker for patients with PA.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Tenascin-C (TNC) is an extracellular matrix protein involved in the tissue construction. Its expression levels have been detected low levels in normal tissues, but high in many tumors. In this study, we aimed to determine the clinical significance of serum TNC levels in patients with pancreatic adenocarcinoma (PA).Materials and Methods: Thirty-three patients with histopathologically confirmed PA diagnosis and sex- and age-matched 30 healthy controls were included into the current study. Serum TNC levels were measured using Enzyme-Linked Immuno Sorbent Assay (ELISA) method.Results: Median age was 59 . Of the patients, 61% were male, 70% had good performance status, and 68% had tumors localized at pancreas head. Pancreaticoduodenectomy and palliative surgery were performed in 5 (15%) and 4 (12%) of the 9 (27%) patients who underwent surgical procedure. Serum TNC levels were found to be significantly higher in patients compared with control group (p<0.001). A significant correlation between serum TNC levels and clinicopathological parameters including age, gender, performance status, tumor location, tumor size, metastasis, chemotherapy response, and laboratory parameters was not detected (p>0.05). Similarly, it was shown that serum TNC levels had no effect on overall survival (p=0.31).Conclusions: Serum TNC level is a diagnostic biomarker for patients with PA. However, it has neither predictive nor prognostic value in this group of patients.

Özet

Amaç: Tenascin-C (TNC) doku yapılanmasında görev alan bir ekstrasellüler matriks proteinidir. Normal dokularda düşük, birçok tümörde ise yüksek düzeyde ekspresyonu tespit edilmiştir. Bu çalışmada, pankreas adenokarsinom (PA)'lı hastalarda serum TNC düzeylerinin klinik önemini belirlenmesi amaçlanmıştır. Gereç ve Yöntem: Çalışmamıza histopatolojik olarak tanısı konfirme edilmiş 33 PA'lı hasta ile yaş-cinsiyet olarak eşleştirilmiş 30 sağlıklı kontrol alındı. Serum TNC düzeyleri, Enzyme-Linked Immuno Sorbent Assay (ELISA) yöntemiyle belirlendi. Bulgular: Ortanca teşhis yaşı 59 idi. Hastaların %61'i erkek, %70'inin performans durumu iyi ve %68'inde tümör lokalizasyonu pankreas başı bölgesindeydi. Cerrahi uygulanan 9 (%27) hastanın; 5 (%15)'ine pankreatikoduodenektomi operasyonu, 4 (%12)'üne ise palyatif cerrahi uygulandı. Serum TNC düzeyleri, hasta grubunda kontrol grubuna göre anlamlı olarak yüksek bulundu (p 0.05). Ek olarak, serum TNC düzeylerinin genel sağkalım üzerinde etkisinin olmadığı gösterildi (p=0.31).Sonuçlar: Serum TNC, PA'lı hastalarda tanısal biyobelirteçtir. Fakat, prediktif ve prognostik değeri mevcut değildir.

🔖

Cite This Article

KARABULUT, S., KARABULUT, M., ALIŞ, H., TAMBAŞ, M., KAPAN, S., KÖNEŞ, O., KARAMAN, Ş., SERİLMEZ, M., TAŞ, F. (2016). Is serum tenascin-C level potential biomarker in pancreatic adenocarcinoma?. Bakırköy Tıp Dergisi, Cilt: 12 - Sayı: 2, 76–82. https://ajindex.com/articles/128661

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96
  2. Midwood KS, Hussenet T, Langlois B, et al. Advances intenascin-C biology. Cell Mol Life Sci 2011; 68: 3175-3199
  3. Guttery DS, Shaw JA, Lloyd K, et al. Expressionof tenascin-C anditsisoforms in thebreast. Cancer Metastasis Rev 2010; 29: 595- 606
  4. Lowy CM, Oskarsson T. Tenascin C in metastasis: A view from the invasive front. Cell Adh Migr 2015; 9: 112-124
  5. Shi M, He X, Wei W, et. al. Tenascin-C induces resistance to apoptosis in pancreatic cancer cell through activation of ERK/NF-?B pathway. Apoptosis 2015; 20: 843-857
  6. Orend G, Chiquet-Ehrismann R. Tenascin-C inducedsignaling in cancer. Cancer Lett 2006; 244: 143-163
  7. Oskarsson T, Acharyya S, Zhang XH, et al. Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat Med 2011; 17: 867-874
  8. Vaidya P, Yosida T, Sakakura T, et al. Combined analysis of expression of c-erbB-2, Ki-67 antigen, and tenascin provides a better prognostic indicator of carcinoma of the papilla of Vater. Pancreas 1996; 12: 196-201
  9. Juuti A, Nordling S, Louhimo J, et al. Tenascin C expression is upregulated in pancreatic cancer and correlates with differentiation. J Clin Pathol 2004; 57: 1151-1155
  10. Franklin O, Öhlund D, Lundin C, et. al. Combining conventional and stroma-derived tumour markers in pancreatic ductal adenocarcinoma. Cancer Biomark 2015; 15: 1-10
  11. Esposito I, Penzel R, Chaib-Harrireche M, et al. Tenascin C and annexin II expression in the process of pancreatic carcinogenesis. J Pathol 2006; 208: 673-685
  12. Estany S, Vicens-Zygmunt V, Llatjós R, et al. Lung fibrotic tenascin-C upregulation is associated with other extracellular matrix proteins and induced by TGF?1. BMC Pulm Med 2014; 14: 120
  13. Gong XG, Lv YF, Li XQ, et al. Gemcitabine resistance induced by interaction between alternatively spliced segment of tenascin-C and annexin A2 in pancreatic cancer cells. Biol Pharm Bull 2010; 33: 1261-1267
  14. Kylänpää L, Hagström J,Lepistö A, et al. Syndecan-1 and tenascin expression in cystic tumors of the pancreas. JOP 2009; 10: 378-382
  15. Degen M, Brellier F, Kain R, et al. Tenascin-W is a novel marker for activated tumor stroma in low-grade human breast cancer and influences cell behavior. Cancer Res 2007; 67: 9169-9179
  16. Degen M, Brellier F, Schenk S, et al. Tenascin-W, a new marker of cancer stroma, is elevated in sera of colon and breast cancer patients